Óscar Gallego

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá et al. · Neuro-Oncology · 2017 · 119 citations · Full text

Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin

Joan Comenge, Cármen G. Sotelo, Francisco M. Romero et al. · PLoS ONE · 2012 · 103 citations · Full text

Nanoparticles, Nanomedicine, Medicinal Chemistry +13

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 103 citations · Full text

Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas

Joan Maurel, Antonio López–Pousa, R. de las Peñas et al. · Journal of Clinical Oncology · 2009 · 73 citations · Full text